homoharringtonine + cytarabine + dexamethasone

This is a combination chemotherapy regimen consisting of three agents: - Homoharringtonine, a cephalotaxine alkaloid that inhibits protein synthesis by binding to the ribosomal A-site, leading to apoptosis in leukemic cells. - Cytarabine, an antimetabolite that inhibits DNA synthesis by acting as a cytosine nucleoside analog, primarily used in the treatment of acute myeloid leukemia (AML). - Dexamethasone, a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties; it also induces apoptosis in certain hematologic malignancies. This combination is used primarily for induction therapy in acute myeloid leukemia (AML), especially in relapsed or refractory cases. The regimen leverages the synergistic effects of these agents to increase remission rates. Homoharringtonine-based regimens have shown efficacy and tolerability as induction therapy for AML[1][3]. Dexamethasone is included for its anti-leukemic and supportive care benefits[6][8][10].

Other names

高三尖杉酯碱 + 阿糖胞苷 + 地塞米松